Sitagliptin NDC 0480-2607

NDC codes

FDA NDC Directory

Product NDC (as listed)0480-2607Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00480-2607Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0480-2607-56	00480260756	30 TABLET, FILM COATED in 1 BOTTLE (0480-2607-56)Marketed from May 28, 2026
0480-2607-98	00480260798	90 TABLET, FILM COATED in 1 BOTTLE (0480-2607-98)Marketed from May 28, 2026

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Sitagliptin
Generic name (nonproprietary): sitagliptin
Active ingredients: Sitagliptin phosphate — 25 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Teva Pharmaceuticals, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 202327
Marketing start: May 28, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Dipeptidyl Peptidase 4 Inhibitors (Mechanism)
Identifiers: Product ID 0480-2607_ab518e96-e35b-40b1-b7e8-b4e01ada32ebSPL ID ab518e96-e35b-40b1-b7e8-b4e01ada32ebSPL set ID 5fa5aa67-455e-4ac6-864d-268a91286432RxCUI 2709603, 2709608, 2709612UNII TS63EW8X6F
Pharmacologic class: Dipeptidyl Peptidase 4 Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400480260756 followed by a unit qualifier and the quantity

Package 00480-2607-56. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 1, 2025.

Indications (excerpt from the label)

Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use Sitagliptin tablets should not be used in patients with type 1 diabetes. Sitagliptin tablets have not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using sitagliptin tablets [see Warnings and Precautions ( 5.1 )]. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 202327

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 202327
Product	Strength	Form · route	Labeler	Product NDC
Sitagliptin	Sitagliptin phosphate 50 mg/1	Tablet, Film coatedOral	Teva Pharmaceuticals, Inc.	0480-2608
Sitagliptin	Sitagliptin phosphate 100 mg/1	Tablet, Film coatedOral	Teva Pharmaceuticals, Inc.	0480-2609